Medication review in Parkinso
Not yet recruiting
- Conditions
- Parkinson's DiseaseTherapy adherenceMedicationPolypharmacy
- Registration Number
- NL-OMON21486
- Lead Sponsor
- Medisch Spectrum Twente
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 198
Inclusion Criteria
The patient has/is:
• Diagnosed with PD according to the UK-brain banking criteria
Exclusion Criteria
The patient has/is:
• Unable to administrate own medications, excluding PD patients with personal or family home caregivers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective of the study is to assess whether a structured medication review improves medication adherence and leads to better quality of life in patients with PD after a follow-up of three months and six months, compared to patients with PD who will not receive a structured medication review during follow-up. Disease-specific quality of life will be measured, using the Parkinson’s Disease Questionnaire-39 (PDQ-39).
- Secondary Outcome Measures
Name Time Method The secondary objectives of the study are measurements of activities in daily life and physical disability, mobility and motor symptoms, non-motor symptoms, cost-effectiveness and health state, and personal carers’ quality of life, by comparing the results of PD patients who receive a medication review with PD patients who will not receive a medication review. The effects will be measured by using the AMC Linear Disability Scale (ALDS), the Non Motor Symptoms Questionnaire (NMSQuest), the EuroQOL-5 Dimensions (EQ-5D), the Visual Analogue Scale (VAS), and the PDQ carer questionnaire.